Expert Interview
Understanding the future of Allogeneic T cell therapy after the EU approval of Atara's Ebvallo
Ticker(s): ATRAInstitution: Children's Hospital Colorado
- Professor of Pediatrics & Director of BMT and Cellular Therapy at Children's Hospital Colorado
- Hematology/Oncology and Bone Marrow Transplantation expert who currently treats 70 patients a month with stem cell transplants
- Oversees NIH funded laboratory studying BMT, T cells, and NK cells; authored over 225 original manuscripts and written numerous book chapters.
Please describe your background and current practice setting
Added By: ben_adminHow many stem cell transplant patients with EBV do you currently manage?
Added By: ben_adminWhat is the current standard of care for these patients?
Added By: ben_adminWhat are your overall thoughts on the recent approval of Ebvallo?
Added By: ben_adminDo you think Allogeneic T cell therapies will become the new standard of care for these patients?
Added By: ben_adminIf the manufacturing process for autologous T cell therapies improves, do you think allogeneic therapies will still be utilized?
Added By: ben_adminRank your excitement for Ebvallo on a scale 1-10?
Added By: ben_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
